相关实验视频
Updated: Jul 15, 2026

16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
35.1K
心上脂肪组织体积的增加可能会对接受过导管大动脉植入术的患者的结果产生不利影响
Kerem Özbek1, Mustafa Dağlı2, Ahmet Balun3
1Department of Cardiology, Ankara Bilkent City Hospital, Ankara, Turkey.
概括
心脂肪组织 (EAT) 体积与跨导管大动脉植入 (TAVI) 后的不良结果有关. 由于严重的大动脉狭窄而接受TAVI的患者的EAT体积较高,预测了主要的心脏和脑血管不良事件.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
- 医疗成像医学成像
背景情况:
- 心脂肪组织 (EAT) 分泌炎症性细胞因子,影响心血管疾病的发展.
- 严重的大动脉狭窄是一种重要的心血管疾病,通常用跨导管大动脉植入物 (TAVI) 治疗.
研究的目的:
- 调查心上脂肪组织 (EAT) 体积与接受TAVI的患者的临床结果之间的关联.
- 确定EAT体积是否是TAVI后主要不良心脏和脑血管终点 (MACCE) 的独立预测指标.
主要方法:
- 对334名接受TAVI治疗严重大动脉狭窄症的患者进行了回顾性分析.
- 量化了EAT体积,并将患有MACCE和没有MACCE的患者进行了比较.
- 为了确定MACCE的预测因素,进行了单变量和多变量Cox比例危险分析.
主要成果:
- 经历MACCE的患者与没有MACCE的患者相比,平均EAT体积显著更高.
- EAT体积与MACCE独立相关 (HR=1.012;95% CI:1.006-1.018;p < 0.001). 这两种结合的结果是:
- 白蛋白水平也是MACCE的一个独立预测因素 (HR = 0.925; 95% CI: 0.866-0.987; p = 0.018).
结论:
- 心脂肪组织体积是严重的大动脉狭窄症TAVI接受患者1年不良结果的重要独立预测因素.
- EAT体积可能在TAVI后心血管事件的病理生理学中发挥关键作用.
相关概念视频
Aortic Regurgitation I: Introduction
IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Aortic Regurgitation IV: Nursing Management
A nurse managing a patient with aortic regurgitation begins with a comprehensive assessment, including a review of the patient's medical history, family history, and lifestyle factors. During the cardiac examination, the nurse listens for heart sounds and checks for signs of valve abnormalities. The nurse also observes for symptoms such as dyspnea, orthopnea, and paroxysmal nocturnal dyspnea and assesses the patient's endurance and daily activity tolerance.Based on the findings, the nurse...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

